- Evotec earned a programme-based payment of $50 million from Bristol Myers Squibb following progress in their molecular glue degraders pipeline.
- The partnership focuses on developing compounds beyond oncology, adding to the potential milestones of the collaboration.
Evotec SE announced the expansion of its strategic partnership with Bristol Myers Squibb to further develop a molecular glue-based pipeline. Evotec has received a $50 million payment from Bristol Myers Squibb, with additional programme-based milestone payments contributing to the overall deal value. The milestone comes from the ongoing development of a molecular glue-based pipeline, with recent progress in expanding the scope of these degraders into therapeutic areas beyond oncology.
This partnership, established in 2018 and extended in May 2022, focuses on developing molecular glue degraders using Bristol Myers Squibb’s proprietary cereblon E3 ligase modulators (CELMoDs). The collaboration has been highly productive, prompting both companies to extend the deal and further develop compounds for high-value therapeutic targets.
The partnership leverages Evotec’s proprietary PanOmics and PanHunter platforms for drug discovery, combining cutting-edge proteomics and transcriptomics with data analysis. According to Dr Cord Dohrmann, Chief Scientific Officer of Evotec, “Our partnership with BMS continues to build an extraordinary pipeline of first-in-class product opportunities, and we look forward to driving the joint portfolio towards clinical validation.”
The collaboration seeks to capitalise on molecular glue degraders, which offer a versatile approach to targeting proteins that conventional drugs cannot. These compounds enable the degradation of previously “undruggable” proteins by inducing interactions with E3 ubiquitin ligases.
Overview of outsourcing trends 
